MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 7, 2008; DOI: 10.1124/mol.108.050609


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.108.050609v1
mol.108.050609v2
74/5/1429    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Borland, M. G.
Right arrow Articles by Peters, J. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borland, M. G.
Right arrow Articles by Peters, J. M.


Received for publication July 16, 2008.
Revised August 6, 2008.
Accepted for publication August 6, 2008.

Ligand Activation of Peroxisome Proliferator-Activated Receptor-{beta}/{delta} (PPAR{beta}/{delta}) Inhibits Cell Proliferation in Human HaCaT Keratinocytes

Michael G. Borland 1, Jennifer E. Foreman 1, Elizabeth E. Girroir 1, Reza Zolfaghari 1, Arun K. Sharma 1, Shantu M. Amin 1, Frank J. Gonzalez 2, A. Catharine Ross 1, Jeffrey M. Peters 1*

1 The Pennsylvania State University 2 National Cancer Institute

* Address correspondence to: E-mail: jmp21{at}psu.edu

Abstract

While there is strong evidence that ligand activation of PAR{beta}/{delta} induces terminal differentiation and attenuates cell growth, some studies suggest that PAR{beta}/{delta} actually enhances cell proliferation. For example, it was recently suggested that retinoic acid (RA) is a ligand for PAR{beta}/{delta} and potentiates cell proliferation by activating PPAR{beta}/{delta}. The present study examined the effect of ligand activation of PAR{beta}/{delta} on cell proliferation, cell cycle kinetics and target gene expression in human HaCaT keratinocytes using two highly specific PAR{beta}/{delta} ligands (GW0742, GW501516) and RA. Both PAR{beta}/{delta} ligands and RA inhibited cell proliferation of HaCaT keratinocytes. GW0742 and GW501516 increased expression of known PAR{beta}/{delta} target genes while RA did not; RA increased expression of known RAR/RXR target genes while GW0742 did not affect these genes. GW0742, GW501516 and RA did not modulate expression of 3-phosphoinositide-dependent protein kinase (PDPK1) or alter Akt phosphorylation. GW0742 and RA increased annexin V staining as quantitatively determined by flow cytometry. The effects of GW0742 and RA were also examined in wild-type and PAR{beta}/{delta}-null primary mouse keratinocytes to determine the specific role of PAR{beta}/{delta} in modulating cell growth. While inhibition of keratinocyte proliferation by GW0742 was PAR{beta}/{delta}-dependent, inhibition of cell proliferation by RA occurred in both genotypes. Results from these studies demonstrate that ligand activation of PAR{beta}/{delta} inhibits keratinocyte proliferation through PAR{beta}/{delta}-dependent mechanisms. In contrast, the observed inhibition of cell proliferation in mouse and human keratinocytes by RA is mediated by PAR{beta}/{delta}-independent mechanisms and is inconsistent with the notion that RA potentiates cell proliferation by activating PAR{beta}/{delta}.


Key words: PPARs, Apoptosis, Mechanisms of cell killing/apoptosis


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. Rieck, W. Meissner, S. Ries, S. Muller-Brusselbach, and R. Muller
Ligand-Mediated Regulation of Peroxisome Proliferator-Activated Receptor (PPAR) {beta}/{delta}: A Comparative Analysis of PPAR-Selective Agonists and All-trans Retinoic Acid
Mol. Pharmacol., November 1, 2008; 74(5): 1269 - 1277.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics